We narrowed to 1,093 results for: plasmid dna

#65453-AAV1

Ready-to-use AAV1 particles produced from AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA (#65453). In addition to the viral particles, you will also receive purified AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA plasmid DNA. TRE-driven, Cre and Flp-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Feb. 14, 2022

Academic Institutions and Nonprofits only

#139505-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#162382-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 13, 2021

Academic Institutions and Nonprofits only

#104496-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE (#104496). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE plasmid DNA. CAG-driven, Cre-dependent jGCaMP7f calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Nov. 13, 2019

Academic Institutions and Nonprofits only

#234438-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-iGluSnFR4f-NGR-WPRE (#234438). In addition to the viral particles, you will also receive purified pAAV-syn-iGluSnFR4f-NGR-WPRE plasmid DNA. Syn-driven, iGluSnFR4f-NGR sensor expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aggarwal et al Nat Methods. 2026 Feb;23(2):417-425. doi

Sept. 22, 2025

Academic Institutions and Nonprofits only

#83900-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#84445-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-drive, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 12, 2017

Academic Institutions and Nonprofits only

#51502-AAV2

Ready-to-use AAV2 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 7, 2018

Academic Institutions and Nonprofits only

#51502-AAV9

Ready-to-use AAV9 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 8, 2018

Academic Institutions and Nonprofits only

#234437-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-iGluSnFR4s-NGR-WPRE (#234437). In addition to the viral particles, you will also receive purified pAAV-syn-iGluSnFR4s-NGR-WPRE plasmid DNA. Syn-driven, iGluSnFR4s-NGR sensor expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aggarwal et al Nat Methods. 2026 Feb;23(2):417-425. doi

Oct. 23, 2025

Academic Institutions and Nonprofits only

#51502-AAV8

Ready-to-use AAV8 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Jan. 26, 2021

Academic Institutions and Nonprofits only

#83898-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-ChR2-mCherry-Fishell-3 (#83898). In addition to the viral particles, you will also receive purified pAAV-mDlx-ChR2-mCherry-Fishell-3 plasmid DNA. mDlx-driven expression of ChR2, fused to mCherry. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 9, 2020

Academic Institutions and Nonprofits only

#83895-AAV8

Ready-to-use AAV8 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

May 22, 2023

Academic Institutions and Nonprofits only

#83897-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#83900-AAV1

Ready-to-use AAV1 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Jan. 26, 2021

Academic Institutions and Nonprofits only

#83894-AAV5

Ready-to-use AAV5 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Sept. 27, 2023

Academic Institutions and Nonprofits only

#51502-AAV5

Ready-to-use AAV5 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Oct. 3, 2019

Academic Institutions and Nonprofits only

#83896-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 9, 2020

Academic Institutions and Nonprofits only

#83897-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#83896-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only